Your browser is no longer supported. Please, upgrade your browser.
ARMP Armata Pharmaceuticals Inc. monthly Stock Chart
ARMP [AMEX]
Armata Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.54 Insider Own63.12% Shs Outstand18.40M Perf Week1.28%
Market Cap58.80M Forward P/E- EPS next Y-0.88 Insider Trans0.00% Shs Float6.90M Perf Month-1.25%
Income-20.10M PEG- EPS next Q-0.27 Inst Own4.70% Short Float0.58% Perf Quarter-2.16%
Sales0.30M P/S196.01 EPS this Y72.10% Inst Trans1.87% Short Ratio2.68 Perf Half Y-15.47%
Book/sh1.34 P/B2.37 EPS next Y32.00% ROA-48.90% Target Price- Perf Year-27.63%
Cash/sh0.86 P/C3.70 EPS next 5Y- ROE-78.70% 52W Range2.52 - 6.92 Perf YTD-2.46%
Dividend- P/FCF- EPS past 5Y-14.90% ROI- 52W High-54.19% Beta1.80
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin- 52W Low25.79% ATR0.18
Employees33 Current Ratio2.40 Sales Q/Q- Oper. Margin- RSI (14)46.13 Volatility1.94% 5.80%
OptionableNo Debt/Eq0.03 EPS Q/Q56.90% Profit Margin- Rel Volume0.85 Prev Close3.17
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume14.78K Price3.17
Recom1.70 SMA20-4.32% SMA50-3.01% SMA200-8.27% Volume12,604 Change0.00%
Jun-19-19Initiated Ladenburg Thalmann Buy $9
Nov-16-20 11:10PM  
Nov-15-20 07:17AM  
Nov-12-20 04:05PM  
Oct-29-20 07:30AM  
Oct-26-20 07:30AM  
Oct-15-20 07:30AM  
Sep-29-20 07:30AM  
Sep-11-20 07:30AM  
Aug-13-20 04:05PM  
Jun-30-20 06:05AM  
Jun-17-20 07:30AM  
May-14-20 04:05PM  
Apr-28-20 08:00AM  
Mar-30-20 07:30AM  
Mar-19-20 04:05PM  
Mar-18-20 08:00AM  
Feb-13-20 08:00AM  
Jan-29-20 08:04AM  
Jan-28-20 07:00AM  
Nov-12-19 04:05PM  
Oct-31-19 10:52AM  
07:05AM  
Oct-21-19 07:05AM  
Oct-16-19 07:05AM  
Oct-10-19 04:05PM  
Sep-19-19 07:05AM  
Sep-12-19 09:00AM  
Aug-14-19 04:05PM  
Aug-02-19 03:27PM  
Aug-01-19 10:30AM  
Jun-18-19 07:01AM  
Jun-03-19 07:01AM  
May-28-19 07:01AM  
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates includes AP-SA02, which is in Phase 1b/2 clinical trial and AP-SA01 that targets staphylococcus aureus, including multidrug-resistant strains. It is also developing and advancing AP-PA02 that is in Phase 1b/2 clinical trial for treating diseases caused by pseudomonas aeruginosa. The company is headquartered in Marina del Rey, California.